Estudo randomizado | Tratamento precoce com fluvoxamina reduziu o risco de cuidado de emergência e internação entre pacientes com COVID-19.

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial – The Lancet Global Health

Comentários:

Expert reaction to study looking at fluvoxamine as a COVID-19 treatment in high-risk outpatients with early-diagnosed COVID-19 – Science Media Centre

The TOGETHER Trial: COVID-19 and Fluvoxamine Take Two – REBEL EM

The antidepressant fluvoxamine can keep COVID-19 patients out of the hospital – ScienceNews

Conteúdos relacionados:

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

Comentário no Twitter

NEW in @LancetGH: Using SSRI #fluvoxamine to treat high-risk outpatients with early-diagnosed #COVID19 reduced the need for prolonged observation in an emergency setting or hospitalisation: largest trial to date. https://t.co/BVtMju74lp @TogetherTrial pic.twitter.com/F1FnZuyqdY

— The Lancet (@TheLancet) October 27, 2021